Aquestive Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Aquestive Therapeutics completed human factors validation and pharmacokinetic studies for Anaphylm (dibutepinephrine) sublingual film, addressing FDA deficiencies from January 2026 Complete Response Letter. The company reaffirms Q3 2026 NDA resubmission and is advancing global regulatory strategy (Canada Q4 2026, EU Q1 2027). Q2 2026 revenues rose 38% to $13.8M (vs. $10.0M prior year); net loss was $22.9M including $11.7M one-time debt extinguishment loss; cash position $98.5M.
Why this rating
Anaphylm resubmission is pivotal for a $292M-market-cap company with $98.5M cash; approval could unlock $75M RTW funding + $20M Oak Tree debt. Routine operating results offset by regulatory progress on lead asset.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.